Table 2.
Important clinical trials of HIV/HBV therapies.
| Trial number | Phase | Status | Sample size | Design |
|---|---|---|---|---|
| NCT01924455 | IV | Completed | 138 | Maraviroc/Placebo |
| NCT00192595 | IV | Completed | 36 | Tenofovir/Zidovudine, lamivudine, efavirenz |
| NCT01751555 | IV | Completed | 100 | TDF/3TC/EFV |
| NCT03115736 | II | Completed | 24 | Tenofovir Alafenamide |
| NCT03547908 | III | Recruiting | 240 | B/FTC/TAF or DTG+FTC/TDF |
| NCT00476463 | II | Completed | 24 | Emtricitabine |
| NCT03797014 | IV | Recruiting | 60 | B/FTC/TAF |
| NCT00127959 | IV | Completed | 24 | Tenofovir/emtricitabine/zidovudine/efavirenz |
| NCT03425994 | – | Active, not recruiting | 275 | Elvitegravir/Cobicistat/Emtricitabine |
| NCT00033163 | II | Completed | 90 | Adefovir dipivoxil/Tenofovir disoproxil fumarate |
| NCT00013702 | II | Competed | 30 | Adefovir |
| NCT00023153 | III | Completed | 100 | Adefovir dipivoxil |
| NCT01125696 | II | Completed | 45 | Zidovudine/lamivudine/lopinavir-ritonavir or Tenofovir/lamivudine/lopinavir-ritonavir |
| NCT00391638 | II/III | Completed | 56 | Peg-interferon Alpha 2a/Tenofovir /Emtricitabine |
| NCT02071082 | III | Completed | 79 | E/C/FTC/TAF |
All the detailed information of clinical trials was registered on the website (ClinicalTrials.gov).
TDF, tenofovir disoproxil fumarate; 3TC, lamivudine; EFV, efavirenz; B, bictegravir; FTC, emtricitabine; TAF, tenofovir alafenamide; DTG, dolutegravir; E, elvitegravir; C, cobicistat.